KRAS and neoplasm: The systemic impact of aberrant immune infiltration in localized tumor tissue was evaluated by comparing the level of immune cells, Igs, blood platelets, and acute phase proteins, such as CRP and hs-CRP in the blood of 335 CRC patients (101 patients tested positive for KRAS-mutation and 234 had KRAS wild-type).